The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B01 | Antithrombotic agents | |
| 3 | B01A | Antithrombotic agents | |
| 4 | B01AC | Platelet aggregation inhibitors excl. heparin | |
| 5 | B01AC27 |
| Active Ingredient | Description | |
|---|---|---|
| Selexipag |
Selexipag is a selective IP receptor agonist distinct from prostacyclin and its analogues. Selexipag is hydrolysed by carboxylesterases to yield its active metabolite, which is approximately 37-fold more potent than selexipag. Stimulation of the IP receptor by selexipag and the active metabolite leads to vasodilatory as well as anti-proliferative and anti-fibrotic effects. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| UPTRAVI Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
